tBID is a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2) with an IC50 of 0.33 μM; it exhibits unprecedented efficacy and selectivity against HIPK2 (Gini coefficient 0.592 across a panel of 76 kinases); it also inhibits HIPK1 and HIPK3, albeit less potently than HIPK2; its mechanism of action is ATP-competitive, binding to the hinge region through hydrophobic interactions involving Val213, Val261, Phe277, Leu280, Met331, Ile345, and the tetrabromo moiety, while the symmetric nitrogen atom at position 3 interacts with catalytic Lys228, playing a crucial role in the binding architecture.